# FibroBiologics, Inc.: overview FBLG · Nasdaq · CIK 1958777 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fblg.md) · [Financials](/companies/fblg/financials.md) · [Filings](/companies/fblg/filings.md) · [Insiders](/companies/fblg/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.01)](/filings/0001193125-25-260774.md) | not reported | [(2.71)](/filings/0001193125-26-197858.md) | [(2.41)](/filings/0001193125-26-328454.md) | [(0.13)](/filings/0001193125-25-260774.md) | not reported | [(1.33)](/filings/0001193125-26-197858.md) | [(0.66)](/filings/0001193125-26-328454.md) | | Free cash flow | $k | [(2,617) d](/filings/0001193125-25-260774.md) | [(3,172) d](/filings/0001193125-26-066965.md) | [(5,318)](/filings/0001193125-26-197858.md) | [(4,197) d](/filings/0001193125-26-328454.md) | [(3,978) d](/filings/0001193125-25-260774.md) | [(3,163) d](/filings/0001193125-26-066965.md) | [(4,364)](/filings/0001193125-26-197858.md) | [(3,291) d](/filings/0001193125-26-328454.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001493152-24-008361.md) | [(0.68)](/filings/0001641172-25-001691.md) | [(0.34)](/filings/0001193125-26-066965.md) | [(0.42)](/filings/0001193125-26-066965.md) | | Free cash flow | $m | not reported | [(6.9)](/filings/0001641172-25-001691.md) | [(12.1)](/filings/0001193125-26-066965.md) | [(16.7)](/filings/0001193125-26-066965.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fblg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cascade Financial Partners, LLC](/funds/2021208.md) | 2026-06-30 | $103.1k | 108,828 | | Added +92,400 | | [Fund Evaluation Group, LLC](/funds/1356249.md) | 2026-06-30 | $49.1k | 51,794 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $28.7k | 30,299 | | Added +690 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $26.3k | 27,769 | | Reduced −39,896 | | [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $23.0k | 24,313 | | New +24,313 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.3k | 18,238 | | Reduced −6,409 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $6.9k | 7,243 | | New +7,243 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $6.0k | 6,380 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.5k | 4,728 | | Added +4,268 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $2.3k | 2,404 | | Added +2,250 | ## Recent filings [All 239 filings](/companies/fblg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 21:15 ET | [8-K](/filings/0001193125-26-418065.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-418065 | | 2026-09-18 | 20:05 ET | [8-K](/filings/0001193125-26-395511.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-395511 | | 2026-09-17 | 20:01 ET | [SCHEDULE 13D](/filings/0001493152-26-043112.md) | Ownership report, active investor | 0001493152-26-043112 | | 2026-09-15 | 11:15 ET | [8-K](/filings/0001193125-26-391310.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-391310 | | 2026-08-24 | 12:48 ET | [8-K](/filings/0001193125-26-362027.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-362027 | | 2026-07-31 | 20:04 ET | [10-Q](/filings/0001193125-26-328454.md) | Quarterly report, period 2026-06-30 | 0001193125-26-328454 | | 2026-07-31 | 13:14 ET | [DEF 14A](/filings/0001193125-26-326818.md) | Proxy statement, period 2026-09-17 | 0001193125-26-326818 | | 2026-07-24 | 20:05 ET | [8-K](/filings/0001193125-26-316067.md) | 3.01 Delisting notice | 0001193125-26-316067 | | 2026-07-09 | 13:31 ET | [8-K](/filings/0001193125-26-299290.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-299290 | | 2026-06-29 | 20:15 ET | [8-K](/filings/0001193125-26-288468.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-288468 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-066965.md), filed Feb 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1958777 - Tickers: FBLG - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.